Factors to consider in managing drug interactions in clinical practice;Facteurs à prendre en considération pour la gestion des interactions médicamenteuses en pratique clinique

Presse Medicale

Volumn 37, Issue 4 PART 2, 2008, Pages 654-664

  Charpiat, Bruno ^a,b   Allenet, Benoit ^b,c   Roubille, Renaud ^b,d   Escofier, Laurence ^b,e   Bedouch, Pierrick ^b,f   Juste, Michel ^b,g   Rose, François Xavier ^b,h   Conort, Ornella ^b,i  

^a CROIX ROUSSE HOSPITAL   (France)

^b la Société française de pharmacie clinique

^c UNIV GRENOBLE ALPES   (France)

^d Centre Hospitalier Lucien Hussel   (France)

^e Centre Hospitalier de Mayenne   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g Service pharmacie   (France)

^h Hotel Dieu CHU Rennes   (France)

ⁱ NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; ITRACONAZOLE; PROTEINASE INHIBITOR;

CLINICAL PRACTICE; COMPUTER SYSTEM; DATA BASE; HUMAN; PREVENTION AND CONTROL; SHORT SURVEY; STATISTICAL SIGNIFICANCE;

EID: 41249097446     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.08.012     Document Type: Short Survey

References (107)

1. Doucet J., Chassagne P., Trivalle C., Landrin I., Pauty M.D., Kadri N., et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc 44 (1996) 944-948
2. Hamilton R.A., Briceland L.L., and Andritz M.H. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 18 (1998) 1112-1120
3. McDonnell P.J., and Jacobs M.R. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 36 (2002) 1331-1336
4. Juurlink D.N., Mamdani M., Kopp A., Laupacis A., and Redelmeier D.A. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289 (2003) 1652-1658
5. Becker M.L., Kallewaard M., Caspers P.W., Visser L.E., Leufkens H.G., and Stricker B.H. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 16 (2007) 641-651
6. Remy N., Lapeyre-Mestre M., Bareille M.P., Bagheri H., and Montastruc J.L. Interactions médicamenteuses : à propos d'une étude prospective pilote en médecine générale libérale. Thérapie 55 (2000) 395-398
7. Guedon-Moreau L., Ducrocq D., Duc M.F., Quieureux Y., L'Hote C., Deligne J., et al. Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59 (2004) 899-904
8. Manchon N.D., Bercoff E., Lemarchand P., Chassagne P., Senant J., and Bourreille J. Fréquence et gravité des interactions médicamenteuses dans une population âgée : étude prospective concernant 639 malades. Rev Med Interne 10 (1989) 521-525
9. Barre E., Bisseux L., Chiadmi F., Toledano A., Cisternino S., Schlatter J., et al. Interactions médicamenteuses dans une population âgée Étude prospective de leur fréquence et de leur gravité auprès de 56 malades. Presse Med 34 (2005) 837-841
10. Doucet J., Kalimoutou S., Chedru C., Remy E., Cabrejo L., Meliot C., et al. Les prescriptions de médicaments anticholinestérasiques sont-elles adaptées au contexte médical au cours de la démence de type Alzheimer ?. Thérapie 61 (2006) 23-27
11. Zamparutti P., and Le Duff M. Évaluation de la fréquence et de la nature des interventions pharmaceutiques effectuées depuis la pharmacie de l'hôpital comparativement à celles effectuées dans une unité de soins. Le Pharmacien Hospitalier 120 (1995) 31-33
12. Dumortier G., Van Nieuwenhuyse V., Zerrouk A., Chebili S., Glikman J., and Degrassat K. Démarche qualité dans le circuit médicament grâce à l'analyse pharmaceutique des ordonnances dans un établissement de soins psychiatriques. Encephale 25 (1999) 323-328
13. Vernardet S., Bossaert S., Livrozet A., Pont E., and Charpiat B. Validation pharmaceutique des prescriptions hospitalières Intervention et analyse sur cinq ans. Presse Med 34 (2005) 990-996
14. Bedouch P., Allenet B., Labarere J., Brudieu E., Chen C., Chevrot D., et al. Diffusion des opinions pharmaceutiques dans le cadre d'une activité de pharmacie clinique en unité de soins. Thérapie 60 (2005) 515-522
15. Gaillard K., Bohand X., Beranger C., Boulliat C., and Guevel C. Évaluation des interventions pharmaceutiques à l'hôpital d'instruction des armées Sainte-Anne dans le cadre d'une dispensation journalière individuelle et nominative. Journal de Pharmacie Clinique 25 (2006) 39-47
16. Garreau I, Derharoutunian C, Roubille R, Galtier H. Assessment of pharmacy interventions after drug orders review: a 34 months retrospective study (july 94 - april 97). In Process in clinical pharmacy, future therapies and clinical pharmacy. Proceedings of the 26th European Symposium on Clinical Pharmacy, Tours 1997, 173-5.
17. Demange C. Analyse pharmaceutique des prescriptions en unité de soins à l'aide de la fiche d'intervention de la Société française de pharmacie clinique. Journal de Pharmacie Clinique 26 (2007) 45-52
18. Roubille R, Charpiat B, Escoffier L, Bedouch P, Juste M, Rose FX et al. Potentiel d'étude et de recherche de la base ACT-IP de la Société Française de Pharmacie Clinique : Illustration avec les interactions médicamenteuses. 2007 (Accepté pour publication).
19. Anonyme. Le dictionnaire Vidal. 82e ed. (2006), Vidal, Paris
20. La Revue Prescrire. Supplément « Interactions Médicamenteuses » de la Revue Prescrire Éviter les effets indésirables par interactions médicamenteuses. Comprendre et décider. Le guide 2007. 2006, Supplément au n° 278, p 1-176.
21. Thériaque. Banque de données sur le médicament, Système d'Information sur les Produits de Santé. Accessible à l'adresse suivante : http://www.theriaque.org/[consulté le 8 mai 2007]
22. Agence française de sécurité sanitaire des produits de santé. Thesaurus : Référentiel national des interactions médicamenteuses (avril 2006). Consultable à l'adresse suivante : http://afssaps.sante.fr/htm/10/iam/indiam.htm
23. Stockley's Drug Interactions. Consultable à l'adresse suivante : https://www.medicinescomplete.com/mc/stockley (date de consultation 7 mai 2007)
24. Drug Interactions Facts. Consultable à l'adresse suivante : http://www.factsandcomparisons.com/(date de consultation 7 mai 2007)
25. Micromedex Consultable à l'adresse suivante : http://www.micromedex.com. (date de consultation 7 mai 2007).
26. Osheroff JA, Teich JM, Middleton BF, Steen EB, Wright A, Detmer DE. White paper: A Roadmap for National Action on Clinical Decision Support June 13, 2006, consultable et téléchargeable à l'adresse suivante: http://www.micromedex.com/index.html].
27. Ferner R.E., and Aronson J.K. Communicating information about drug safety. BMJ 333 (2006) 143-145
28. Anonyme. Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro (Issued 4/1997, Posted 4/8/1997); Updated draft guidance http://www.fda.gov/cder/drug/drugInteractions/guidance.htm]
29. Anonyme. In Vivo Drug Metabolism/Drug Interaction Studies - Study Design, Data Analysis, and Recommendations for Dosing and Labeling (Issued 11/24/1999, Posted 11/24/1999); http://www.fda.gov/cder/drug/drugInteractions/guidance.htm.
30. Woodward K.N. The potential impact of the use of homeopathic and herbal remedies on monitoring the safety of prescription products. Hum Exp Toxicol 24 (2005) 219-233
31. Goldstein L.H., Elias M., Ron-Avraham G., Biniaurishvili B.Z., Madjar M., Kamargash I., et al. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards. Br J Clin Pharmacol (2007; Apr 10) [Epub ahead of print]
32. Michaud L.B., Karpinski J.P., Jones K.L., and Espirito J. Dietary supplements in patients with cancer: Risks and key concepts, part 1. Am J Health Syst Pharm 64 (2007) 369-381
33. Fusier I., Freville C., Tollier C., and Husson M.C. Discordances d'informations sur les interactions médicamenteuses : analyse par un auteur d'une base de données informatisée sur le médicament pour les professionnels de santé. Journal de Pharmacie Clinique 23 (2004) 25-30
34. Fusier I., Tollier M., Husson M.C., and Infovigilance. Infovigilance : impact sur le contenu des résumés des caractéristiques du produit. Journal de Pharmacie Clinique 23 (2004) 69-74
35. Bergk V., Haefeli W.E., Gasse C., Brenner H., and Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 61 (2005) 327-335
36. Jurus V., Bossaert S., and Charpiat B. Estimation du nombre et de la nature des interactions médicamenteuses concernant les médicaments antirétroviraux. Journal de Pharmacie Clinique 25 (2006) 153-159
37. Centre National Hospitalier d'Information sur le Médicament Anticancéreux : utilisation pratique 5ème édition 2004, XXV, 4-5.
38. Schwiertz V., Bertin C., Henry A., and Charpiat B. Estimation du nombre et de la nature des interactions médicamenteuses des anticancéreux. Bull Cancer 94 (2007) 477-482
39. Chao S.D., and Maibach H.I. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 6 (2005) 105-111
40. British National Formulary. Consultable à l'adresse suivante : http://www.bnf.org
41. Vitry A.I. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63 (2007) 709-714
42. Trifiro G., Corrao S., Alacqua M., Moretti S., Tari M., Caputi A.P., et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 62 (2006) 582-590
43. Loke Y.K., Price D., Derry S., and Aronson J.K. Case reports of suspected adverse drug reactions--systematic literature survey of follow-up. BMJ 332 (2006) 335-339
44. Johnston P.E., and Milstone A. Probable interaction of bergamottin and cyclosporine in a lung transplant recipient. Transplantation 79 (2005) 746
45. Schwarz U.I., Johnston P.E., Bailey D.G., Kim R.B., Mayo G., and Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol 62 (2006) 485-491
46. Yasui-Furukori N., and Kaneko S. Digitalis intoxication induced by paroxetine co-administration. Lancet 367 (2006) 788
47. Bateman D.N., Thanacoody H.K., and Waring W.S. Digitalis intoxication induced by paroxetine co-administration. Lancet 368 (2006) 1962-1963
48. Hallberg P., and Melhus H. Digitalis intoxication induced by paroxetine co-administration. Lancet 368 (2006) 1963
49. Juurlink D.N., Mamdani M.M., Kopp A., Herrmann N., and Laupacis A. A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. Br J Clin Pharmacol 59 (2005) 102-107
50. Morii M., Ueno K., Ogawa A., Kato R., Yoshimura H., Wada K., et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 68 (2000) 613-616
51. Lorenz M., Wolzt M., Weigel G., Puttinger H., Horl W.H., Fodinger M., et al. Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. Am J Kidney Dis 43 (2004) 1098-1103
52. Mudge D.W., Atcheson B., Taylor P.J., Sturtevant J.M., Hawley C.M., Campbell S.B., et al. The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation 77 (2004) 206-209
53. Ducray P.S., Banken L., Gerber M., Boutouyrie B., and Zandt H. Absence of an interaction between iron and mycophenolate mofetil absorption. Br J Clin Pharmacol 62 (2006) 492-495
54. Tsuruoka S., Ioka T., Wakaumi M., Sakamoto K., Ookami H., and Fujimura A. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 79 (2006) 389-396 Erratum in: Clin Pharmacol Ther. 2006; 80: 645
55. Whomsley R., Strolin-Benedetti M., and Baltes E. Comment on severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency. Clin Pharmacol Ther 80 (2006) 715-716 author reply 716-7
56. Suda K.J., Garey K.W., and Danziger L.H. Treatment failures secondary to drug interactions with divalent cations and fluoroquinolone. Pharm World Sci 27 (2005) 81-82
57. Mallet L., and Huang A. Coadministration of gatifloxacin and multivitamin preparation containing minerals: potential treatment failure in an elderly patient. Ann Pharmacother 39 (2005) 150-152
58. Quain R.D., Barton T.D., Fishman N.O., Weiner M.G., and Lautenbach E. Coadministration of oral levofloxacin with agents that impair its absorption: potential impact on emergence of resistance. Int J Antimicrob Agents 26 (2005) 327-330
59. Barton T.D., Fishman N.O., Weiner M.G., LaRosa L.A., and Lautenbach E. High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: risk factors and potential implications. Infect Control Hosp Epidemiol 26 (2005) 93-99
60. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 (2003) 1758-1764
61. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
62. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80 (2006) 61-74
63. Guay D.R. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother 2 (2004) 14-23
64. UroXatral. [package Insert] (2003), Sanofi-Synthelabo Inc, New York
65. Wilde M.I., Fitton A., McTavish D., and Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 45 (1993) 410-429
66. Weideman R.A., Berstein I.A., and McKinney W.P. Pharmacist recognition of potential drug interactions. Am J Health Syst Pharm 56 (1999) 1524-1529
67. Halkin H., Katzir I., Kurman I., Jan J., and Malkin B.B. Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 69 (2001) 260-265
68. Tamblyn R., Huang A., Perreault R., Jacques A., Roy D., Hanley J., et al. The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care. CMAJ 169 (2003) 549-556
69. Malone D.C., Hutchins D.S., Haupert H., Hansten P., Duncan B., Van Bergen R.C., et al. Assessment of potential drug-drug interactions with a prescription claims database. Am J Health Syst Pharm 62 (2005) 1983-1991
70. Hazlet T.K., Lee T.A., Hansten P.D., and Horn J.R. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash) 41 (2001) 200-204
71. Hansten P.D. Drug interaction management. Pharm World Sci 25 (2003) 94-97
72. Mille F., Bourdon O., Fontan J.E., and Brion F. Évaluation de la spécificité d'un système de détection automatisée des interactions médicamenteuses. Acta Pharmacol Biol Clin 12 (2005) 361-368
73. Weingart S.N., Toth M., Sands D.Z., Aronson M.D., Davis R.B., and Phillips R.S. Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 163 (2003) 2625-2631
74. Murphy J.E., Forrey R.A., and Desiraju U. Community pharmacists' responses to drug-drug interaction alerts. Am J Health Syst Pharm 61 (2004) 1484-1487
75. Magnus D., Rodgers S., and Avery A.J. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 27 (2002) 377-382
76. Li Wan Po A. Drug-drug interactions and adverse drug reactions: the bollards and flashing lights syndrome. J Clin Pharm Ther 30 (2005) 97-99
77. van der Sijs H., Aarts J., Vulto A., and Berg M. Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc 13 (2006) 138-147
78. Indermitte J., Beutler M., Bruppacher R., Meier C.R., and Hersberger K.E. Management of drug-interaction alerts in community pharmacies. J Clin Pharm Ther 32 (2007) 133-142
79. Smith W.D., Hatton R.C., Fann A.L., Baz M.A., and Kaplan B. Evaluation of drug interaction software to identify alerts for transplant medications. Ann Pharmacother 39 (2005) 45-50
80. Peng C.C., Glassman P.A., Marks I.R., Fowler C., Castiglione B., and Good C.B. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm 9 (2003) 513-522
81. Puckett Jr. W.H., and Visconti J.A. An epidemiological study of the clinical significance of drug-drug interactions in a private community hospital. Am J Hosp Pharm 28 (1971) 247-253
82. Glintborg B., Andersen S.E., and Dalhoff K. Drug-drug interactions among recently hospitalised patients--frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61 (2005) 675-681
83. Naunton M., Duyvendak M., Peterson G.M., and Brouwers J.R. Comments on Glintborg et al. 's drug-drug interactions study (EJCP 2005; 61:675-681). Eur J Clin Pharmacol 62 (2006) 159-160
84. Duggal H.S. Delirium associated with amitriptyline/fluconazole drug. Gen Hosp Psychiatry 25 (2003) 297-298
85. Robinson R.F., Nahata M.C., and Olshefski R.S. Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 34 (2000) 1406-1409
86. Dorsey S.T., and Biblo L.A. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med 18 (2000) 227-229
87. Newberry D.L., Bass S.N., and Mbanefo C.O. A fluconazole/amitriptyline drug interaction in three male adults. Clin Infect Dis 24 (1997) 270-271
88. Schier J.G., Howland M.A., Hoffman R.S., and Nelson L.S. Fatality from administration of labetalol and crushed extended-release nifedipine. Ann Pharmacother 37 (2003) 1420-1423
89. Peynaud D., Charpiat B., Vial T., Gallarvardin M., and Ducerf C. Tacrolimus severe overdosage after intake of masked grapefruit in orange marmalade. Eur J Clin Pharmacol 63 (2007) 721-722
90. Mur Lalaguna M.A., Cobo Campos R., Hurtado Gomez M.F., and Martinez Tutor M.J. Estudio de las interacciones entre fármacos antirretrovirales y tratamiento concomitante. Farm Hosp 27 (2003) 84-92
91. Yu D.T., Peterson J.F., Seger D.L., Gerth W.C., and Bates D.W. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf 14 (2005) 755-767
92. Jansman F.G., Jansen A.J., Coenen J.L., de Graaf J.C., Smit W.M., Sleijfer D.T., et al. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer. Am J Health Syst Pharm 62 (2005) 1788-1793
93. Jansman F.G., Idzinga F.S., Smit W.M., de Graaf J.C., Coenen J.L., Sleijfer D.T., et al. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer. Clin Ther 27 (2005) 327-335
94. Drug interactions: cytochrome P450 system. Date de dernière mise à jour 24/04/07 consultable à l'adresse suivante http://medicine.iupui.edu/flockhart/table.htm]
95. Liang X.J., and Aszalos A. Multidrug transporters as drug targets. Curr Drug Targets 7 (2006) 911-921
96. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112 (2006) 457-473
97. Samer C.F., Piguet V., Dayer P., and Desmeules J.A. Polymorphisme génétique et interactions médicamenteuses : leur importance dans le traitement de la douleur. Can J Anaesth 52 (2005) 806-821
98. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., and Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 102 (2006) 146-150
99. Laugesen S., Enggaard T.P., Pedersen R.S., Sindrup S.H., and Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77 (2005) 312-323
100. Tirkkonen T., and Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 76 (2004) 639-647
101. Saito M., Yasui-Furukori N., Nakagami T., Furukori H., and Kaneko S. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 25 (2005) 527-532
102. Ray W.A., Murray K.T., Meredith S., Narasimhulu S.S., Hall K., and Stein C.M. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 (2004) 1089-1096
103. De Bruin M.L., Langendijk P.N., Koopmans R.P., Wilde A.A., Leufkens H.G., and Hoes A.W. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 63 (2007) 216-223
104. van Roon E.N., Flikweert S., le Comte M., Langendijk P.N., Kwee-Zuiderwijk W.J., Smits P., et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf 28 (2005) 1131-1139
105. Smith W.E., Ray M.D., and Shannon D.M. Physicians' expectations of pharmacists. Am J Health Syst Pharm 59 (2002) 50-57
106. Zillich A.J., McDonough R.P., Carter B.L., and Doucette W.R. Influential characteristics of physician/pharmacist collaborative relationships. Ann Pharmacother 38 (2004) 764-770
107. da Costa Saar S.R., and Trevizan M.A. Los roles profesionales de un equipo de saud : la vision de sus integrantes. Rev Lat Am Enfermagem 15 (2007) 106-112